Chief Marketing Officer
Donald C. Manning
Donald C. Manning (MD, PhD) is the Chief Medical Officer at Adynxx Inc. Dr. Donald C. Manning joined Adynxx in January 2012 continuing a 14 year career in the pharmaceutical industry where he has held positions of increasing scope and responsibility starting at,
Novartis as Global Head of Analgesics Development to Vice President & Neurosciences Therapeutic Area, Head at Celgene, Vice President & Head of Clinical Development at Alpharma, VP of Medical Affairs at King Pharma, Executive Vice President & Chief Medical Officer at Shionogi Inc.
Don received his BSc in Physiology and Biochemistry from McGill University in Montreal. He earned his PhD in the laboratory of Dr. Solomon H. Snyder at Johns Hopkins University where he also earned his MD. He pursued residency training in Anesthesiology, fellowship training in Regional Anesthesia and Pain Management and a Post-Doctoral Fellowship in the Department of Neurosurgery under Dr. James Campbell all at Johns Hopkins.
Vice President Development
Scott Harris
Scott Harris (MS, RAC,) Vice President, Regulatory Affairs & Product Development at Adynxx Inc.
Scott Harris joined Adynxx in 2010 as Vice President of Regulatory Affairs and Product Development. He is responsible for global regulatory oversight, quality assurance and CMC. His career has spanned 15 years in the biotech industry, starting as a basic scientist in the area of cell and tumor biology, before moving into Regulatory Affairs and Quality Assurance.
He has held positions of increasing responsibility at,
Biosite, Inc.,
Angstrom Pharmaceutical,
Attenuon,
BioMarin Pharmaceutical,
also his own independent consulting business.
Prior to joining Adynxx, he was head of Regulatory Affairs and Quality Assurance for Corthera until its acquisition by Novartis.
Scott obtained his MS in Regulatory Affairs from San Diego State University and his BS in Biochemistry and Cell Biology from UC San Diego.
Director
Dennis Podlesak
Dennis Podlesak is the Board Chairman Adynxx Inc.
Dennis Podlesak is a Partner at Domain Associates LLC, an exclusively life science focused venture capital firm.
Since joining the Domain team, Dennis has served as an active investor and a founder of a number of Domain companies, and also as a Chief Executive Officer or Executive Chairman for a number of Domains promising growth companies.
Dennis first served as the Chief Executive Officer of Peninsula Pharmaceuticals and after building the company, led the sale of Peninsula to Johnson & Johnson.
In his next role, Dennis was a founder and the Chief Executive Officer of Cerexa, and led the sale of Cerexa to Forest Laboratories.
In his next role, Dennis was again a founder and the Chief Executive Officer of Calixa Therapeutics and successfully led the growth and sale of Calixa to Cubist Pharmaceuticals.
Director
Eckard Weber
Eckard Weber is the Board Director at Adynxx Inc.
Dr. Weber joined Domain in 2001 as a Partner where he specializes in creating companies around promising new pharmaceutical products.
He has been founding CEO of multiple biopharmaceutical companies in the Domain portfolio including,
Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia, Domain Antibacterial Acquisition Corporation, NovaCardia, Novacea, Novalar Pharmaceuticals, Ocera Therapeutics, Orexigen Therapeutics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics, Tragara Pharmaceuticals.
He currently serves as interim CEO of Sonexa Therapeutics.
He is Chairman of the Board at, Ascenta Therapeutics, Ocera Therapeutics, Orexigen Therapeutics, Sequel Pharmaceuticals, Tobira Therapeutics.
Dr. Weber is an Observer on the Board of Syndax Pharmaceuticals.
A Board member of Adynxx.
Director
Eric Heil
Eric Heil is the Board Observer at Adynxx Inc.
Mr. Heil joined Domain in 2008, and became an Entrepreneur-In-Residence in 2012.
In 2011, while at Domain, Mr. Heil co-founded RightCare Solutions, Inc., a Domain healthcare IT portfolio company.
After successfully closing its Series A financing in October 2012, Mr. Heil became President & CEO of RightCare Solutions, Inc.
From 2008-2012, Mr. Heil assisted with the review of new investment opportunities and helped existing Domain portfolio companies with financing strategies and would take an active role in business development processes.
In particular, Mr. Heil was involved in Domain’s public equity investment in Achillion Pharmaceuticals and private investments in Adynxx and Afferent Pharmaceuticals.
In 2009 and early 2010, Mr. Heil served as Director of Business Development for Corthera, a Domain portfolio company, which was acquired by Novartis in February 2010.
Director
Julien Mamet
Julien Mamet (PhD) is the Founder & Chief Scientific Officer at Adynxx Inc.
Dr. Julien Mamet founded Adynxx in October 2007 and served as Chief Executive Officer and President through December 2010.
He currently serves as Chief Scientific Officer and is a member of the Board of Directors. Julien has extensive pharmaceutical experience in the areas of neuroscience and drug discovery and is the inventor of the AYX technology platform.
Prior to Adynxx, he worked at the SCRIPPS Research Institute and Novartis Genomics Institute in San Diego, California.
Julien obtained his PhD in Pain and Pharmacology at the Institute of Molecular and Cellular Pharmacology in Nice-Sophia Antipolis, France, where he worked in the laboratory of Prof. Michel Lazdunski, a worldwide leader in pain research with over 600 publications in the field.
His graduate work focused on the identification and validation of novel targets for pain drug therapies.
Director
Stan Abel
Stan Abel is the Board Director at Adynxx Inc.
He joined the Adynxx board in 2008, bringing to the company more than 20 years of operational, development and financial management experience.
Stan most recently served as Chief Executive Officer of Corthera, Inc., from October 2007 through the successful sale of the company to Novartis in February 2010.
Prior to joining Corthera, Stan served as the Chief Financial Officer of Cerexa, Inc. from its inception in July 2005 through the successful sale of the company to Forest Laboratories in January 2007.
Prior to Cerexa Stan was the Chief Financial Officer of Peninsula Pharmaceuticals, Inc. from January 2003 through the sale of the company to Johnson & Johnson in June 2005.
Stan was responsible for all financial activities of the company, raising over $70M in private financing and leading the company through the initial public offering process.
Director
William Martin
William Martin is the Director, Operations at Adynxx Inc.
William Martin joined Adynxx in January 2012 as Director, Operations. His responsibilities include marketing and commercial strategy as well as support of financing and business development activities.
Prior to joining Adynxx Bill ran his own consulting business, advising venture-backed and public life sciences companies on transaction finance and valuation, marketing and commercial strategy, and business development.
Bill was Director, Operations at Corthera where he supported business development activities leading to a successful sale to Novartis in February, 2010.
His previous experienece also includes The Boston Consulting Group and AIR Worldwide, a company that models the risk of property damage due to natural disasters.
Bill received his MBA from the MIT Sloan School of Management.
He holds a Bachelor’s Degree in Engineering Sciences & Economics from Dartmouth College.
Director
Kimberly Hebert
Kimberly Hebert is the Director, Clinical Operations at Adynxx Inc.
Kimberly Hebert joined Adynxx in October 2011 as Director, Clinical Operations.
Her career has spanned 14 years in the biotech industry, starting as a Clinical Operations Assistant, and has held positions of increasing responsibility at,
Alliance Pharmaceutical, Corp.,
Neurocrine Biosciences, Inc.,
NovaCardia, Inc.,
Merck & Co., Inc. (after NovaCardia was acquired by Merck in 2007).
Most recently, she led clinical operations for an international Phase 3 study sponsored by Corthera, Inc., and continued to lead operations for the project after Corthera’s acquisition by Novartis in early 2010.
Kim studied in the Clinical Trials Design and Management Extension program at the University of California, San Diego in 2001-2002 and previously studied at the University of Colorado, Boulder.
Dina Gonzalez
Dina Gonzalez is the Corporate Controller at Adynxx Inc.
Dina Gonzalez joined Adynxx in 2010 as Controller.
Prior to joining Adynxx, Dina served as Controller of Corthera until its acquisition by Novartis. She is responsible for the accounting and business operations of the company.
Her career has spanned 17 years in the finance industry, starting as a cost accountant in the semiconductor industry.
She has held positions of increasing responsibility at,
VLSI Technology,
Philips Semiconductors,
Cerexa (acquired by Forest Laboratories),
Corthera (acquired by Novartis),
as well as consulting with a variety of venture backed companies.
Dina obtained her MBA from St. Marys University, San Antonio, Texas.
She also holds a BBA in Accounting from St. Marys University, San Antonio, Texas.
Her MPA in Accounting from the University of Texas at San Antonio.